ALK Alkemy Capital Investments Plc

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM ANY PART OF AN OFFER TO SELL OR ISSUE, OR A SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY SECURITIES IN THE UNITED STATES, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL OR TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION. NO PUBLIC OFFERING OF THE FUNDRAISE SHARES IS BEING MADE IN ANY SUCH JURISDICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF SUCH JURISDICTIONS.

THIS ANNOUNCEMENT IS NOT FOR PUBLIC RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION NO. 596/2014 ("MAR") AS IN FORCE IN THE UNITED KINGDOM PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

17 February 2025

Alkemy Capital Investments Plc

Placing to raise £1.035 million

Alkemy Capital Investments plc ("Alkemy") (LSE: ALK) is pleased to announce that it has raised £1.035 million in an oversubscribed placing of 828,000 new ordinary shares at a placing price of £1.25 per share ("Placing Shares").

This includes a subscription of £150,000 from director Paul Atherley, £75,000 from director Sam Quinn, £50,000 from director Vikki Jeckell and £10,000 from director Helen Pein. Quark Financial was the Financial Advisor to the transaction. 

The net proceeds will be used to further the development of TVL's lithium hydroxide processing faclility in Teesside and for general working capital purposes.   

Following the placing, the directors will have the following beneficial shareholdings in the Company:

^*Includes a subscription of £50,000 via Lionshead Consulting Limited and £25,000 via Silvertree Partners, in which Mr Quinn has an interest.

Subscribers in the placing will be entitled to one warrant for every two shares subscribed at an exercise price of £2 per share for two years from the date of issuance. If at any time during the two year period the Company's shares price exceeds £4 for a ten day period an accelerator provision will apply and the Company may elect to enforce the exercise of the warrants.

In addition Alkemy has issued 100,000 new ordinary shares in relation to fees payable to an adviser ("Fee Shares").

The placing and issue of the Placing Shares and Fee Shares are conditional upon and an application will be made for 928,000 ordinary shares to be admitted to the official list (Standard Segment) of the FCA and to trading on the Main Market of the London Stock Exchange ("Admission") and Admission is expected to occur at 8.00 a.m. on 24 February 2025.

In accordance with the FCA's Disclosure Guidance and Transparency Rules, the Company confirms that following Admission, the Company's enlarged issued ordinary share capital will comprise 9,742,851 ordinary shares each with a right to vote and with no shares held in treasury. Therefore, following Admission, the above figure may be used by shareholders in the Company as the denominator for the calculations to determine if they are required to notify their interest in, or a change to their interest in the Company, under the FCA's Disclosure Guidance and Transparency Rules.

In addition, the Company has issued 65,000 warrants exerciseable at £0.88 per share, 50,000 warrants exerciseable at £1.25 per share and 120,000 warrants exerciseable at £1.75 per share.

Further information

For further information, please visit the Company's website: www.alkemycapital.co.uk or www.teesvalleylithium.co.uk

-Ends-

Forward Looking Statements

This news release contains forward‐looking information. The statements are based on reasonable assumptions and expectations of management and Alkemy provides no assurance that actual events will meet management's expectations. In certain cases, forward‐looking information may be identified by such terms as "anticipates", "believes", "could", "estimates", "expects", "may", "shall", "will", or "would". Although Alkemy believes the expectations expressed in such forward‐looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those projected. In addition, factors that could cause actual events to differ materially from the forward-looking information stated herein include changes in market conditions, changes in metal prices, general economic and political conditions, environmental risks, and community and non-governmental actions. Such factors will also affect whether Alkemy will ultimately receive the benefits anticipated pursuant to relevant agreements. This list is not exhaustive of the factors that may affect any of the forward‐looking statements. These and other factors should be considered carefully and readers should not place undue reliance on forward-looking information.

The Notification of Dealing Form provided in accordance with the requirements of the Market Abuse Regulation in relation to the transaction listed above is set out below.